Abstract
In 2008 cancer was identified by the World Health Organization (WHO) as one of four threats to human health and development. Since the early published reports of the first chemotherapeutic, mustine, in 1946, the anti-cancer drug and development industry has grown into a multi-billion dollar business enterprise. Worldwide, the rates of new cancer cases and deaths has been steadily increasing each year, with the estimation by the WHO-sponsored GLOBOCAN cancer database, that at current rates, nearly 13 million cancer deaths will be reported in 2030. The recent successes of monoclonal antibodies (mAbs), an important class of glycoprotein, and their multivalent and drug conjugated derivatives over the past 30 years have led to the approval of 12 monoclonal antibodies for use in cancer treatment by the FDA. Modern recombinant and engineering techniques have led to an explosion of antibody platforms that can be attributed to great gains in clinical efficacy. This review discusses and outlines a sample of mAbs currently approved for cancer treatment by the FDA, as well as antibody platforms in the research pipeline and clinic that have been engineered for greater tumor penetration, binding, and efficacy.
Keywords: Antibody engineering, antibody therapeutics, cancer therapy, multivalent antibody.
Protein & Peptide Letters
Title:Antibodies and their Multivalent Constructs for Cancer Therapy
Volume: 21 Issue: 10
Author(s): Qing Li, Li Yi and Peter Marek
Affiliation:
Keywords: Antibody engineering, antibody therapeutics, cancer therapy, multivalent antibody.
Abstract: In 2008 cancer was identified by the World Health Organization (WHO) as one of four threats to human health and development. Since the early published reports of the first chemotherapeutic, mustine, in 1946, the anti-cancer drug and development industry has grown into a multi-billion dollar business enterprise. Worldwide, the rates of new cancer cases and deaths has been steadily increasing each year, with the estimation by the WHO-sponsored GLOBOCAN cancer database, that at current rates, nearly 13 million cancer deaths will be reported in 2030. The recent successes of monoclonal antibodies (mAbs), an important class of glycoprotein, and their multivalent and drug conjugated derivatives over the past 30 years have led to the approval of 12 monoclonal antibodies for use in cancer treatment by the FDA. Modern recombinant and engineering techniques have led to an explosion of antibody platforms that can be attributed to great gains in clinical efficacy. This review discusses and outlines a sample of mAbs currently approved for cancer treatment by the FDA, as well as antibody platforms in the research pipeline and clinic that have been engineered for greater tumor penetration, binding, and efficacy.
Export Options
About this article
Cite this article as:
Li Qing, Yi Li and Marek Peter, Antibodies and their Multivalent Constructs for Cancer Therapy, Protein & Peptide Letters 2014; 21 (10) . https://dx.doi.org/10.2174/0929866521666140626102802
DOI https://dx.doi.org/10.2174/0929866521666140626102802 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Novel VEGF<sub>121</sub>-VEGF<sub>165</sub> Fusion Attenuates Angiogenesis and Drug Resistance via Targeting VEGFR2-HIF-1α-VEGF<sub>165</sub>/Lon Signaling Through PI3K-AKT-mTOR Pathway
Current Cancer Drug Targets Tumour-Specific Uptake of Anti-Cancer Drugs: The Future is Here
Current Drug Metabolism LNA Antisense: A Review
Current Physical Chemistry QSPR and Flow Cytometry Analysis (QSPR-FCA): Review and New Findings on Parallel Study of Multiple Interactions of Chemical Compounds with Immune Cellular and Molecular Targets
Current Drug Metabolism Supercritical Fluid Particle Design of DPI Formulations (Review)
Current Pharmaceutical Design Antiviral Activity of Phytochemicals: A Comprehensive Review
Mini-Reviews in Medicinal Chemistry Cancer Stem Cells: How can we Target them?
Current Medicinal Chemistry Epidemiology and Pathology of Malignant Mesothelioma
Current Respiratory Medicine Reviews Critical Update and Emerging Trends in Imatinib Treatment for Gastrointestinal Stromal Tumor
Reviews on Recent Clinical Trials Valproic Acid As Anti-Cancer Drug
Current Pharmaceutical Design Sirtuin Modulators: Mechanisms and Potential Clinical Implications
Current Medicinal Chemistry Celecoxib and Dimethylcelecoxib Block Oxidative Phosphorylation, Epithelial-Mesenchymal Transition and Invasiveness in Breast Cancer Stem Cells
Current Medicinal Chemistry Current and Emerging Systemic Therapy in Gastro-Esophageal Cancer “The Old and New Therapy for Metastatic Disease, The Role of Adjuvant and Neoadjuvant Therapy for Localized Disease”
Current Clinical Pharmacology Irreversible LSD1 Inhibitors: Application of Tranylcypromine and Its Derivatives in Cancer Treatment
Current Topics in Medicinal Chemistry Animal Venoms have Potential to Treat Cancer
Current Topics in Medicinal Chemistry SAR, QSAR and Docking of Anticancer Flavonoids and Variants: A Review
Current Topics in Medicinal Chemistry Targeting Indoleamine 2,3-dioxygenase (IDO) to Counteract Tumour- Induced ImmuneDysfunction: From Biochemistry to Clinical Development
Endocrine, Metabolic & Immune Disorders - Drug Targets Anti-tumor Drug Targets Analysis: Current Insight and Future Prospect
Current Drug Targets Regulation of Runx2 and Its Signaling Pathways by MicroRNAs in Breast Cancer Metastasis
Current Protein & Peptide Science Nano Approaches to Enhance Pharmacokinetic and Pharmacodynamic Activity of Plant Origin Drugs
Current Nanoscience